Cipla
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
Cipla vs Ajanta Pharma Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Ajanta Pharma
Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
Result Snapshot
Revenue₹6,541 Cr₹1,422 Cr
PAT₹543 Cr₹267 Cr
EBITDA Margin15%23%
Sentimentbullishbullish
Key Quotes
We are expecting to launch this product within the coming months. Our Goa facility together with two US facilities is well equipped to support the launch of all four respiratory assets planned for FI27.
Our revenue from operations grew by 21%. While margins grew by 18%. Reflecting strong operating performance alongside continued investments to support future growth.